{
  "ticker": "SNT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969343",
  "id": "02969343",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250715",
  "time": "0926",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250715/pdf/06lt27lwx90zlf.pdf",
  "summary": "### Summary of ASX Announcement:  \n**Type: Clinical Trial Update (Material R&D Milestone)**  \n\n- **Key Catalyst:** First patient dosed in Phase 1c SATELLITE trial for SNT-6302 (topical LOX inhibitor) targeting keloid scars.  \n- **Market Potential:** Addresses unmet need in keloid/hypertrophic scar market (>US$3.5bn annually).  \n- **Upcoming Catalyst:** Phase 1 trial for next-gen agent SNT-9465 (hypertrophic scars) to begin late July 2025.  \n- **Previous Data:** SNT-6302 showed 30% collagen reduction in prior SOLARIA2 study.  \n\n**Omitted:** Trial design details, investigator commentary, non-material pipeline updates.  \n\n*No material capital markets/trading actions (e.g., capital raising, financials) identified.*",
  "usage": {
    "prompt_tokens": 2526,
    "completion_tokens": 186,
    "total_tokens": 2712,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-14T23:46:21.006235"
}